BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 32470159)

  • 1. Surgical outcomes of patients with duodenal vs pancreatic neuroendocrine tumors following pancreatoduodenectomy.
    Dong DH; Zhang XF; Lopez-Aguiar AG; Poultsides G; Rocha F; Weber S; Fields R; Idrees K; Cho C; Spolverato G; Maithel SK; Pawlik TM
    J Surg Oncol; 2020 Sep; 122(3):442-449. PubMed ID: 32470159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes of Surgical and Endoscopic Resection of Duodenal Neuroendocrine Tumours (NETs): a Systematic Review of the Literature.
    Dasari BVM; Al-Shakhshir S; Pawlik TM; Shah T; Marudanayagam R; Sutcliffe RP; Mirza DF; Muiesan P; Roberts KJ; Isaac J
    J Gastrointest Surg; 2018 Sep; 22(9):1652-1658. PubMed ID: 29869091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trends in the Number of Lymph Nodes Evaluated Among Patients with Pancreatic Neuroendocrine Tumors in the United States: A Multi-Institutional and National Database Analysis.
    Sahara K; Tsilimigras DI; Mehta R; Moro A; Paredes AZ; Lopez-Aguiar AG; Rocha F; Kanji Z; Weber S; Fisher A; Fields R; Krasnick BA; Idrees K; Smith PM; Poultsides GA; Makris E; Cho C; Beems M; Dillhoff M; Maithel SK; Endo I; Pawlik TM
    Ann Surg Oncol; 2020 Apr; 27(4):1203-1212. PubMed ID: 31838609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Duodenal neuroendocrine tumors: Impact of tumor size and total number of lymph nodes examined.
    Zhang XF; Wu XN; Tsilimigras DI; Poultsides G; Rocha F; Abbott DE; Fields R; Idrees K; Cho C; Maithel SK; Pawlik TM;
    J Surg Oncol; 2019 Dec; 120(8):1302-1310. PubMed ID: 31680243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New Nodal Staging for Primary Pancreatic Neuroendocrine Tumors: A Multi-institutional and National Data Analysis.
    Zhang XF; Xue F; Dong DH; Lopez-Aguiar AG; Poultsides G; Makris E; Rocha F; Kanji Z; Weber S; Fisher A; Fields R; Krasnick BA; Idrees K; Smith PM; Cho C; Beems M; Lv Y; Maithel SK; Pawlik TM
    Ann Surg; 2021 Jul; 274(1):e28-e35. PubMed ID: 31356277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surgical treatment of neuroendocrine tumors in the second portion of the duodenum: a single center experience and systematic review of the literature.
    Iwasaki T; Nara S; Kishi Y; Esaki M; Shimada K; Hiraoka N
    Langenbecks Arch Surg; 2017 Sep; 402(6):925-933. PubMed ID: 27915372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regional lymphadenectomy is indicated in the surgical treatment of pancreatic neuroendocrine tumors (PNETs).
    Hashim YM; Trinkaus KM; Linehan DC; Strasberg SS; Fields RC; Cao D; Hawkins WG
    Ann Surg; 2014 Feb; 259(2):197-203. PubMed ID: 24253141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal surgical management of unifocal vs. multifocal NF-PNETs: a respective cohort study.
    Kim J; Hong SS; Kim SH; Hwang HK; Kang CM
    World J Surg Oncol; 2024 Apr; 22(1):115. PubMed ID: 38671431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of recurrence after resection of well-differentiated non-functioning pancreatic neuroendocrine tumors.
    Tan QQ; Wang X; Yang L; Chen YH; Tan CL; Zhu XM; Ke NW; Liu XB
    Medicine (Baltimore); 2020 Jun; 99(24):e20324. PubMed ID: 32541455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic index of lymphadenectomy among patients with pancreatic neuroendocrine tumors: A multi-institutional analysis.
    Wu L; Sahara K; Tsilimigras DI; Maithel SK; Poultsides GA; Rocha FG; Weber SM; Fields RC; Idrees K; Cho CS; Shen F; Pawlik TM;
    J Surg Oncol; 2019 Dec; 120(7):1080-1086. PubMed ID: 31468550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Duodenal, ampullary, and pancreatic neuroendocrine tumors: Oncologic outcomes are driven by tumor biology and tissue of origin.
    Schmocker RK; Wright MJ; Ding D; Javed AA; Cameron JL; Lafaro K; Burns WR; He J; Wolfgang CL; Burkhart RA
    J Surg Oncol; 2021 Feb; 123(2):416-424. PubMed ID: 33125737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of tumor size and nodal status on recurrence of nonfunctional pancreatic neuroendocrine tumors ≤2 cm after curative resection: A multi-institutional study of 392 cases.
    Dong DH; Zhang XF; Poultsides G; Rocha F; Weber S; Fields R; Idrees K; Cho C; Maithel SK; Pawlik TM;
    J Surg Oncol; 2019 Dec; 120(7):1071-1079. PubMed ID: 31571225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Multi-institutional Analysis of Duodenal Neuroendocrine Tumors: Tumor Biology Rather than Extent of Resection Dictates Prognosis.
    Margonis GA; Samaha M; Kim Y; Postlewait LM; Kunz P; Maithel S; Tran T; Berger N; Gamblin TC; Mullen MG; Bauer TW; Pawlik TM
    J Gastrointest Surg; 2016 Jun; 20(6):1098-105. PubMed ID: 27008594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Recurrence Between Pancreatic and Duodenal Neuroendocrine Neoplasms After Curative Resection: A Single-Institution Analysis.
    Masui T; Sato A; Nakano K; Uchida Y; Yogo A; Anazawa T; Nagai K; Kawaguchi Y; Takaori K; Uemoto S
    Ann Surg Oncol; 2018 Feb; 25(2):528-534. PubMed ID: 29164413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of Lymph Node Dissection for Non-metastatic Pancreatic Neuroendocrine Tumors: A Propensity Score-Weighted Analysis of the National Cancer Database.
    Mao R; Zhao H; Li K; Luo S; Turner M; Cai JQ; Blazer D
    Ann Surg Oncol; 2019 Sep; 26(9):2722-2729. PubMed ID: 31209670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-Term Outcomes after Spleen-Preserving Distal Pancreatectomy for Pancreatic Neuroendocrine Tumors: Results from the US Neuroendocrine Study Group.
    Sahara K; Tsilimigras DI; Moro A; Mehta R; Dillhoff M; Heidsma CM; Lopez-Aguiar AG; Maithel SK; Rocha FG; Kanji Z; Abbott DE; Fisher A; Fields RC; Krasnick BA; Idrees K; Smith PM; Poultsides GA; Makris E; Cho CS; Beems M; Endo I; Pawlik TM
    Neuroendocrinology; 2021; 111(1-2):129-138. PubMed ID: 32040951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Malignant pancreatic neuroendocrine tumour: lymph node ratio and Ki67 are predictors of recurrence after curative resections.
    Boninsegna L; Panzuto F; Partelli S; Capelli P; Delle Fave G; Bettini R; Pederzoli P; Scarpa A; Falconi M
    Eur J Cancer; 2012 Jul; 48(11):1608-15. PubMed ID: 22129889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Value of Lymph Node Status and Extent of Lymphadenectomy in Pancreatic Neuroendocrine Tumors Confined To and Extending Beyond the Pancreas.
    Conrad C; Kutlu OC; Dasari A; Chan JA; Vauthey JN; Adams DB; Kim M; Fleming JB; Katz MH; Lee JE
    J Gastrointest Surg; 2016 Dec; 20(12):1966-1974. PubMed ID: 27714644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of lymph node metastasis in pancreatic neuroendocrine tumors by contrast enhancement characteristics.
    Mizumoto T; Toyama H; Terai S; Mukubou H; Yamashita H; Shirakawa S; Nanno Y; Sofue K; Kido M; Ajiki T; Fukumoto T
    Pancreatology; 2017; 17(6):956-961. PubMed ID: 28964660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pancreaticoduodenectomy and metastasectomy for metastatic pancreatic neuroendocrine tumors.
    Chawla A; Williams RT; Sich N; Clancy T; Wang J; Ashley S; Pezzi C; Swanson R
    J Surg Oncol; 2018 Nov; 118(6):983-990. PubMed ID: 30212595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.